Company Overview
About Rosebud Biosciences
Rosebud Biosciences is a San Carlos-based drug discovery company that accelerates therapeutic development for rare diseases by screening drug candidates against patient-derived organoids — miniature 3D organ models grown from patients' own cells with matching genetic mutations — using robotic automation and machine learning to identify compounds that correct disease phenotypes at a scale impossible with traditional cell line testing. Founded in 2020 and backed by Y Combinator, NSF, and other investors with $440,000 in revenue, Rosebud has achieved Stanford-validated research breakthroughs published in prestigious scientific journals, including discovering a novel drug target for pediatric heart disease.
Business Model & Competitive Advantage
Rosebud's platform addresses a fundamental problem in rare disease drug development: most rare diseases affect small patient populations (under 200,000 patients in the US), making it economically and logistically difficult to run large clinical trials. Patient-derived organoids — grown from patient biopsy or iPSC (induced pluripotent stem cell) material — provide a laboratory model that matches the actual genetic architecture of individual patients' disease, enabling more predictive pre-clinical screening than generic cell lines. Rosebud's automation infrastructure creates organoids at scale and screens therapeutic libraries against them.
Competitive Landscape 2025–2026
In 2025, Rosebud Biosciences competes in the patient-derived model drug discovery and rare disease platform market with Hubrecht Organoid Technology (HUB, a leading organoid CRO), Champions Oncology (patient-derived xenograft testing), and academic rare disease organoid programs for patient-derived drug screening services. The organoid technology field has matured significantly — Nature has published multiple studies validating organoid drug response prediction. The rare disease focus is strategically important: FDA Orphan Drug Designation, breakthrough therapy pathways, and smaller patient recruitment requirements make rare disease a more capital-efficient development path for preclinical-stage companies. The 2025 strategy focuses on building the organoid disease model library for key rare disease indications, establishing CRO (contract research organization) services for pharma partners, and advancing internal therapeutic programs from the computational hits identified in organoid screening.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Rosebud Biosciences is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Rosebud Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Rosebud Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Rosebud Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Rosebud Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →